Ramy Abdelnaby: Exploring The Timing of Antiplatelet Administration In Minor Stroke Post-Thrombolysis
Ramy Abdelnaby, Consultant Neurologist / Oberarzt at RWTH Aachen University Hospital, shared on LinkedIn about a recent article by Hui-Sheng Chen et al, published in European Heart Journal:
”Exploring the timing of antiplatelet administration in minor stroke post-thrombolysis, the EAST trial offers a comprehensive insight.
Conducted across multiple centers in China, this double-blind, randomized study evaluated the efficacy and safety of early antiplatelet treatment within 6 hours of intravenous thrombolysis in patients with mild neurological deficits.
Despite the high expectations, the trial concluded there’s no significant difference in achieving excellent functional outcomes at 90 days between the early treatment group and placebo.
This challenges existing paradigms and emphasizes the need for cautious decision-making in early antiplatelet therapy.”
Title: Early antiplatelet treatment for minor stroke following thrombolysis: the EAST trial
Authors: Hui-Sheng Chen, Yu Cui, Xiao-Qiu Li, Xin-Hong Wang, Chang-Hao Jiang, Jing Li, Zhi-Mei Yuan, Li-Wei Zhao, Nan Kong, Hai-Ning Mi, Jiang Lu, Hong Zhang, You-Jun Liu, Er-Qiang Wang, Yan Yang, Cheng-Guang Song, Yi Zhang, Shu-Yao Wang, Hong-Guo Dai, Yi Yang, Shi-Mei Geng, Rong Yin, Duo-Lao Wang, Thanh N. Nguyen
Read the Full Article on European Heart Journal
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 21, 2026, 12:34Kellie Machlus: Animal Models Driving Progress in Thrombosis Research
-
Aug 21, 2026, 12:08Amy Allen Whitfield: Helping to Proceed Bleeding Disorders Care
-
Aug 21, 2026, 11:53Jan Terje Andersen: Harnessing Placental Biology for Therapeutic Engineering
-
Aug 21, 2026, 11:02Severe ITP, Critical Bleeding, and the Challenge of Platelet Testing – RPTH Journal
-
Aug 21, 2026, 10:46Arwa Z. Al-Riyami: Looking Ahead to ISBT Muscat 2029
-
Aug 21, 2026, 10:42Janine Mothershed: What Is Romiplostim and How Does It Work in Immune Thrombocytopenia?
-
Aug 21, 2026, 10:33Omar Alkharabsheh: Excited to Build the Future of Hematologic Malignancy Care in Central Florida
-
Aug 21, 2026, 10:23Salvador Payán Pernía: Tailoring Therapy in Sickle Cell Disease – Mitapivat and the Path Toward Personalized Combination Care
-
Aug 21, 2026, 10:10Pete Stibbs: The Evolving Landscape of VTE Management